| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Are epigenetic drugs for diabetes and obesity at our door step?
|
Arguelles, Andrix O.
|
|
2016
|
21 |
3 |
p. 499-509
11 p.
|
article
|
| 2 |
Assessment of cognitive safety in clinical drug development
|
Roiser, Jonathan P.
|
|
2016
|
21 |
3 |
p. 445-453
9 p.
|
article
|
| 3 |
A unique multiattribute method to predict success of emerging drug targets
|
De, Sangeetha
|
|
2016
|
21 |
3 |
p. 385-394
10 p.
|
article
|
| 4 |
Contents page 2
|
|
|
2016
|
21 |
3 |
p. ii-
1 p.
|
article
|
| 5 |
Contents page 1
|
|
|
2016
|
21 |
3 |
p. i-
1 p.
|
article
|
| 6 |
Critical considerations for developing nucleic acid macromolecule based drug products
|
Muralidhara, Bilikallahalli K.
|
|
2016
|
21 |
3 |
p. 430-444
15 p.
|
article
|
| 7 |
Designing and incorporating a real world data approach to international drug development and use: what the UK offers
|
Bate, Andrew
|
|
2016
|
21 |
3 |
p. 400-405
6 p.
|
article
|
| 8 |
Developing timely insights into comparative effectiveness research with a text-mining pipeline
|
Chang, Meiping
|
|
2016
|
21 |
3 |
p. 473-480
8 p.
|
article
|
| 9 |
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity
|
Gerhard, Danielle M.
|
|
2016
|
21 |
3 |
p. 454-464
11 p.
|
article
|
| 10 |
Enforcing your IP rights
|
Quiney, Rebecca
|
|
2016
|
21 |
3 |
p. 377-378
2 p.
|
article
|
| 11 |
Financing drug discovery via dynamic leverage
|
Montazerhodjat, Vahid
|
|
2016
|
21 |
3 |
p. 410-414
5 p.
|
article
|
| 12 |
Identifying targets for antibiotic development using omics technologies
|
Pulido, Marina R.
|
|
2016
|
21 |
3 |
p. 465-472
8 p.
|
article
|
| 13 |
Improving the drug development process by reducing the impact of adverse events: the case of cataracts considered
|
Smith, Andrew F.
|
|
2016
|
21 |
3 |
p. 510-516
7 p.
|
article
|
| 14 |
Integrating biophysics with HTS-driven drug discovery projects
|
Folmer, Rutger H.A.
|
|
2016
|
21 |
3 |
p. 491-498
8 p.
|
article
|
| 15 |
Is time an extra dimension in 3D cell culture?
|
Asthana, Amish
|
|
2016
|
21 |
3 |
p. 395-399
5 p.
|
article
|
| 16 |
Multidrug co-crystals: towards the development of effective therapeutic hybrids
|
Thipparaboina, Rajesh
|
|
2016
|
21 |
3 |
p. 481-490
10 p.
|
article
|
| 17 |
Patent production is a prerequisite for successful exit of a biopharmaceutical company
|
Saotome, Chikako
|
|
2016
|
21 |
3 |
p. 406-409
4 p.
|
article
|
| 18 |
Split protein biosensor assays in molecular pharmacological studies
|
Wehr, Michael C.
|
|
2016
|
21 |
3 |
p. 415-429
15 p.
|
article
|
| 19 |
The changing model of big pharma: impact of key trends
|
Gautam, Ajay
|
|
2016
|
21 |
3 |
p. 379-384
6 p.
|
article
|
| 20 |
Translational Medicine Guide transforms drug development processes: the recent Merck experience
|
Dolgos, Hugues
|
|
2016
|
21 |
3 |
p. 517-526
10 p.
|
article
|
Journal description